Search
AstraZeneca COVID-19 Vaccine
go.drugbank.com/drugs/DB15656ApprovedInvestigationalclots in association with thrombocytopenia - a causal link with the vaccine has not been proven, but is possible and requires further analysis. … Upon review, the European Medicines Agency (EMA) determined that the vaccine was not associated with a higher overall risk of blood clots, but that it may be associated with very rare instances of blood
Vepdegestrant
go.drugbank.com/drugs/DB19006ApprovedInvestigational[A275508, A275509] On May 1, 2026, the FDA granted approval for vepdegestrant tablets under the trade name VEPPANU. … [A275507, A275509] It serves as an advanced option to address the clinical challenge of endocrine-resistant breast cancer subtypes.
Xanthan gum
go.drugbank.com/drugs/DB11253ApprovedXanthan gum is a direct food additive permitted for direct addition to food for human consumption by the FDA. It is used as a thickening agent and stabilizer in emulsions. … Xanthan gum is a polysaccharide gum derived from* Xanthomonas campestris* by a pure-culture fermentation process and purified by recovery with isopropyl alcohol.
Peginterferon alfa-2a
go.drugbank.com/drugs/DB00008ApprovedInvestigationalPeginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. … Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763] … [A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification.
Colestipol
go.drugbank.com/drugs/DB00375Approvedbe good candidates for using the agent owing to its physical effects on the gut. … results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaPheniprazine
go.drugbank.com/drugs/DB09250ApprovedWithdrawnPheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDalteparin
go.drugbank.com/drugs/DB06779ApprovedInvestigationalDalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. … Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Products: FRAGMIN 5000IE P FO FER SI, FRAGMIN P FO 5000IE FER+SINefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnNefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. … Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeNintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigationalNintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). … nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to